UY27596A1 - Formulación oral de fludara purísimo con liberación rátida del ingrediente - Google Patents

Formulación oral de fludara purísimo con liberación rátida del ingrediente

Info

Publication number
UY27596A1
UY27596A1 UY27596A UY27596A UY27596A1 UY 27596 A1 UY27596 A1 UY 27596A1 UY 27596 A UY27596 A UY 27596A UY 27596 A UY27596 A UY 27596A UY 27596 A1 UY27596 A1 UY 27596A1
Authority
UY
Uruguay
Prior art keywords
fludara
rapid release
purisimate
ingredient
oral formulation
Prior art date
Application number
UY27596A
Other languages
English (en)
Inventor
Heil Wolfgang
Tilstam Ulf
Lipp Ralph
Johannes-Wilhelm Tack
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7711168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27596A1 publication Critical patent/UY27596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Las presente invención se refiere a una formulacición para comprimido de liberación rápida con Fludara en una pureza de 99,19 % ( Fludara purísimo) como ingredientes activo en una composición definida de impurezas residualles.
UY27596A 2001-12-20 2002-12-19 Formulación oral de fludara purísimo con liberación rátida del ingrediente UY27596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10164510A DE10164510A1 (de) 2001-12-20 2001-12-20 Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes

Publications (1)

Publication Number Publication Date
UY27596A1 true UY27596A1 (es) 2003-07-31

Family

ID=7711168

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27596A UY27596A1 (es) 2001-12-20 2002-12-19 Formulación oral de fludara purísimo con liberación rátida del ingrediente

Country Status (30)

Country Link
US (1) US7148207B2 (es)
EP (1) EP1455760B1 (es)
JP (2) JP2005519043A (es)
KR (1) KR100884685B1 (es)
CN (1) CN1306929C (es)
AR (1) AR037965A1 (es)
AT (1) ATE303797T1 (es)
AU (1) AU2002349043B2 (es)
BR (1) BR0215265A (es)
CA (1) CA2471396A1 (es)
DE (2) DE10164510A1 (es)
DK (1) DK1455760T3 (es)
EC (1) ECSP045185A (es)
ES (1) ES2248624T3 (es)
HK (1) HK1077741A1 (es)
HR (1) HRP20040648B1 (es)
IL (2) IL162555A0 (es)
JO (1) JO2363B1 (es)
MX (1) MXPA04006005A (es)
NO (1) NO20043063L (es)
NZ (1) NZ533701A (es)
PE (1) PE20030639A1 (es)
RS (1) RS50398B (es)
RU (1) RU2318496C2 (es)
SA (1) SA03240091B1 (es)
TW (1) TWI255187B (es)
UA (1) UA78741C2 (es)
UY (1) UY27596A1 (es)
WO (1) WO2003053418A1 (es)
ZA (1) ZA200405735B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201190243A1 (ru) * 2009-05-19 2013-01-30 Гриндекс, Э Джоинт Сток Кампани Стабильная фармацевтическая композиция флударабина фосфата
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
CN101947208B (zh) * 2010-10-09 2012-05-23 江苏奥赛康药业股份有限公司 一种供注射用的磷酸氟达拉滨组合物及其制备方法
CN102091046B (zh) * 2011-02-12 2012-07-18 海南锦瑞制药股份有限公司 一种磷酸氟达拉滨冻干粉针剂及其制备方法
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN111423458A (zh) * 2020-04-29 2020-07-17 东南大学 磷酸氟达拉滨杂质h对照品的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
DE3323621A1 (de) * 1982-07-08 1984-03-01 Yamasa Shoyu K.K., Choshi, Chiba Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier
US5110919A (en) * 1989-12-04 1992-05-05 Ash Stevens, Inc. Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates
FR2701027B1 (fr) * 1993-02-01 1997-07-18 Warner Lambert Co Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate.
DE19543052A1 (de) 1995-11-06 1997-05-07 Schering Ag Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
SK283475B6 (sk) * 1997-12-11 2003-08-05 Schering Aktiengesellschaft Spôsob výroby lítnych, sodných, draselných, vápenatých a horečnatých solí fludarabín-fosfátu, spôsob čistenia pri výrobe fludarabín-fosfátu a fludarabín-fosfát s čistotou najmenej 99,5 %
CN1237958C (zh) 1998-06-11 2006-01-25 法玛西雅厄普约翰美国公司 一种非缓释的、非咀嚼的药物片剂组合物
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
WO2001014348A1 (en) 1999-08-20 2001-03-01 The Scripps Research Institute Formation of heterocycles
EP1175220B1 (en) 1999-12-08 2005-04-27 Pharmacia Corporation Nanoparticulate eplerenone compositions
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
EP1237555A2 (en) * 1999-12-16 2002-09-11 PHARMACIA & UPJOHN COMPANY Implant composition containing melengestrol acetate and trenbolone acetate
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets

Also Published As

Publication number Publication date
IL162555A (en) 2008-03-20
UA78741C2 (en) 2007-04-25
JP2005519043A (ja) 2005-06-30
RU2318496C2 (ru) 2008-03-10
TWI255187B (en) 2006-05-21
HRP20040648A2 (en) 2004-10-31
ZA200405735B (en) 2006-01-25
SA03240091B1 (ar) 2006-11-25
KR20040073501A (ko) 2004-08-19
EP1455760A1 (de) 2004-09-15
BR0215265A (pt) 2004-12-07
RS50398B (sr) 2009-12-31
AU2002349043B2 (en) 2007-08-16
AU2002349043A1 (en) 2003-07-09
US7148207B2 (en) 2006-12-12
AR037965A1 (es) 2004-12-22
MXPA04006005A (es) 2004-09-27
RU2004122479A (ru) 2005-05-20
CN1306929C (zh) 2007-03-28
IL162555A0 (en) 2005-11-20
ES2248624T3 (es) 2006-03-16
JP2006137771A (ja) 2006-06-01
JO2363B1 (en) 2006-12-12
RS53304A (en) 2006-10-27
KR100884685B1 (ko) 2009-02-18
EP1455760B1 (de) 2005-09-07
CN1617713A (zh) 2005-05-18
ATE303797T1 (de) 2005-09-15
CA2471396A1 (en) 2003-07-03
DE10164510A1 (de) 2003-07-10
NZ533701A (en) 2006-03-31
NO20043063L (no) 2004-07-19
HK1077741A1 (en) 2006-02-24
DK1455760T3 (da) 2006-01-02
TW200305428A (en) 2003-11-01
PE20030639A1 (es) 2003-08-28
PL370792A1 (en) 2005-05-30
HRP20040648B1 (en) 2012-11-30
DE50204203D1 (de) 2005-10-13
US20030176391A1 (en) 2003-09-18
ECSP045185A (es) 2004-08-27
WO2003053418A1 (de) 2003-07-03

Similar Documents

Publication Publication Date Title
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
GT199900203A (es) Composiciones de celecoxib.
ECSP066715A (es)
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
MXPA04004974A (es) Composiciones farmaceuticas que comprenden metformina y glibenclamida para tratamiento de diabetes mellitus tipo ii.
GT200200078A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes.
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
UY27596A1 (es) Formulación oral de fludara purísimo con liberación rátida del ingrediente
BRPI0411702B8 (pt) uso de ácido hialurônico para preparar composições para o tratamento de aftas da cavidade oral
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
MX2022007707A (es) Comprimidos de edoxaban.
NO20033699L (no) Stabil farmasöytisk formulering omfattende torsemidmodifikasjon II
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
CR7380A (es) Formulacion oral de fludara purisimo con liberacion rapida del ingrediente activo
RU2008115908A (ru) Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
CU23299A3 (es) Formulaciã"n oral de fludara purã simo con liberaciã"n rã pida del ingrediente activo
AR026451A1 (es) Compuestos heterociclicos sililados
MD20040296A (ro) Compoziţie farmaceutică, conţinând oxcarbazepină cu eliberare prelungită a ingredientului activ
WO2001095890A3 (en) Oral pharmaceutical compositions containing terbinafine
BR0105471A (pt) Formulações à base de própolis para uso odontológico
MXPA04006675A (es) Composicion farmaceutica que comprende glitazona y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
MD2230G2 (ro) Unguent sulfurat

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126